RxDoctor Payments Data

Warren Pleskow, MD

Internal Medicine · Encinitas, CANPI 1942313036

Payments from drug & device makers

$1,602,986in general payments, 2019–2025

Across 243 payments — averaging $6596.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$680K
  • Amphastar Pharmaceuticals, Inc.$276K
  • Teva Pharmaceuticals USA, Inc.$129K
  • GSK$112K
  • Astrazeneca AB$110K
  • Cipla USA Inc.$107K
  • plus $190K from 11 others
$418,081in research payments, 2019–2025

Across 38 payments — averaging $11,002 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Hikma Pharmaceuticals USA$265K
  • Teva Pharmaceuticals USA, Inc.$148K
  • Chiesi USA, Inc.$2K
  • Cipla USA Inc.$2K

What the payments were for

  • Consulting fees$32,75568%
  • Speaking & faculty fees$10,26521%
  • Travel & lodging$2,7646%
  • Food & beverage$2,1474%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,602,986 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$714,347
Medicare patients
158
Services billed
15,588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab13$48,646
MounjaroTirzepatide35$36,020
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$20,215
Advair HfaFluticasone Propion/Salmeterol17$8,435
LinzessLinaclotide11$5,781
PaxlovidNirmatrelvir/Ritonavir16$2,858
Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl44$2,745
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,521
Telmisartan20$1,388
Ipratropium Bromide41$1,243
Wixela InhubFluticasone Propion/Salmeterol12$1,144
Albuterol Sulfate HfaAlbuterol Sulfate25$1,068
Levothyroxine Sodium43$944
Atorvastatin Calcium74$686
Azithromycin102$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$112,232$20,21523 claims
PfizerPaxlovid$32$2,85816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →